Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Papillomavirus Infections 2Neoplasms 2Liver Neoplasms 2Liver Diseases 2Carcinoma, Hepatocellular 2Virus Diseases 1Stomach Neoplasms 1Rheumatic Diseases 1Primary Graft Dysfunction 1Liver Failure, Acute 1Liver Failure 1HIV Infections 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Adenocarcinoma 1

Interventions

Gemcitabine 5130-nm albumin-bound paclitaxel 5Albumin-Bound Paclitaxel 4napabucasin 3Ocoxin 3Irinotecan 3Fluorouracil 3Paclitaxel 2Oxaliplatin 2Nivolumab 2Leucovorin 2Cyclophosphamide 2Capecitabine 2Bevacizumab 2trifluridine tipiracil drug combination 1trametinib 1pralsetinib 1pembrolizumab 1ozanimod 1halofantrine 1guadecitabine 1ficlatuzumab 1Ursodeoxycholic Acid 1Sorafenib 1Radiotherapy 1Pemetrexed 1Oviposition 1Nadroparin 1Lenalidomide 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Digestive System Diseases × halofantrine × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡